Biography
Dr. Andrews is Richard Metzner Endowed Chair in Clinical Neuropharmacology, and Professor of Psychiatry & Biobehavioral Sciences and Chemistry & Biochemistry at the University of California, Los Angeles. She is a member of the Semel Institute for Neuroscience & Human Behavior, the Hatos Center for Neuropharmacology, and the California NanoSystems Institute. Dr. Andrews received her B.S. in Chemistry from the Pennsylvania State University and earned her Ph.D. in Chemistry as a U.S. Department of Education Fellow working at the National Institute of Mental Health, where she was later a postdoctoral fellow and senior staff fellow. At the NIMH, Andrews and her mentor, Dr. Dennis Murphy, discovered and characterized a novel serotonin neurotoxin, 2-NH2-MPTP. Dr. Andrews was also instrumental in early studies on serotonin transporter deficient mice. Andrews is a member of the Society for Neuroscience, American Chemical Society, and Society for Electroanalytical Chemistry. She has been the recipient of an NIH Fellows Award for Research Excellence, an Eli Lily Outstanding Young Analytical Chemist Award, an American Parkinsons Disease Association Research Award, and a NARSAD Independent Investigator Award. She is a elected member of the American College of Neuropsychopharmacology, a fellow of the Collegium Internationale Neuropsychopharmacologicum, and a Serotonin Club elected councilor. Dr. Andrews is also Associate Editor for ACS Chemical Neuroscience.
At UCLA, Andrews leads efforts in basic and translational research on anxiety and depression, and at the nexus of nanoscience and neuroscience. Andrews interdisciplinary research team of neuroscientists, biologists, chemists, and engineers focuses on understanding how the serotonin system and particularly, the serotonin transporter, modulate neurotransmission to influence complex behaviors including anxiety, mood, stress responsiveness, and learning and memory. Genetic and pharmacologic mouse models and human gene variants are studied to understand the molecular basis of serotonin system function associated with the etiology and treatment of mood and anxiety disorders. Nanomaterials are designed for fundamental studies on neurotransmitter recognition by native and nonnative binding partners (aptamers) and for the development of in vivo nanobiosensors and functionally directed proteomics.
Publications
A selected list of publications:
Andrews Anne M, Daws Lynette C
What's old is new
ACS chemical neuroscience,
2013; 4(1):
1-2.
Shuster M J, Vaish A, Cao H H, Guttentag A I, McManigle J E, Gibb A L, Martinez M M, Nezarati R M, Hinds J M, Liao W-S, Weiss P S, Andrews A M
Patterning small-molecule biocapture surfaces: microcontact insertion
printing vs. photolithography
Chemical communications (Cambridge, England),
2011; 47(38):
10641-3.
Leuchter Andrew F, Cook Ian A, Hamilton Steven P, Narr Katherine L, Toga Arthur, Hunter Aimee M, Faull Kym, Whitelegge Julian, Andrews Anne M, Loo Joseph, Way Baldwin, Nelson Stanley F, Horvath Steven, Lebowitz Barry D
Biomarkers to predict antidepressant response
Current psychiatry reports,
2010; 12(6):
553-62.
Daws, L. C., Andrews, A. M., Gerhardt, G. A.
Electrochemical techniques and advances in psychopharmacology,
Encyclopedia of Psychopharmacology,
2010; I.P.Stolerman, Ed., in press, Springer: New York:
.
Andrews, A. M.
Does chronic antidepressant treatment increase extracellular serotonin?,
Frontiers in Neuroscience,
2009; 3(2):
p. 246-247.
Shuster, M. J., Vaish, A., Szapacs, M. E., Anderson, M. E., Weiss, P. S., and Andrews, A. M.
Biospecific recognition of tethered small molecules diluted in self-assembled monolayers
Advanced Materials ,
2008; 20:
p. 164-167.
Guiard Bruno P, David Denis J P, Deltheil Thierry, Chenu Franck, Le Maître Erwan, Renoir Thibault, Leroux-Nicollet Isabelle, Sokoloff Pierre, Lanfumey Laurence, Hamon Michel, Andrews Anne M, Hen René, Gardier Alain M
Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal
hyperserotonergic phenotype
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP),
2008; 11(1):
79-92.
Murphy Dennis L, Fox Meredith A, Timpano Kiara R, Moya Pablo R, Ren-Patterson Renee, Andrews Anne M, Holmes Andrew, Lesch Klaus-Peter, Wendland Jens R
How the serotonin story is being rewritten by new gene-based
discoveries principally related to SLC6A4, the serotonin transporter
gene, which functions to influence all cellular serotonin systems
Neuropharmacology,
2008; 55(6):
932-60.
Mullen, T. J., Srinivasan, C., Shuster, M. J., Horn, M. W., Andrews, A. M., and Weiss, P. S.
Hybrid approaches to nanometer-scale patterning: Exploiting tailored intermolecular interactions
Journal of Nanoparticle Research,
2008; 10(8):
1231-1240.
Mullen, T. J., Srinivasan, C., Hohman, J. N., Gillmor, S. D., Shuster, M. J., Horn, M. W., Andrews, A. M., and Weiss, P. S.
Microcontact insertion printing
Applied Physics Letters,
2007; 90(6):
p. 063114 (063111-063113).
Kim Dong-Kyu, Tolliver Teresa J, Huang Su-Jan, Martin Bradley J, Andrews Anne M, Wichems Christine, Holmes Andrew, Lesch Klaus-Peter, Murphy Dennis L
Altered serotonin synthesis, turnover and dynamic regulation in
multiple brain regions of mice lacking the serotonin transporter
Neuropharmacology,
2005; 49(6):
798-810.
Unger Erica L, Mazzola-Pomietto Pascale, Murphy Dennis L, Andrews Anne M
2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine]
depletes serotonin and norepinephrine in rats: a comparison with
2'-CH(3)-MPTP
[1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine]
The Journal of pharmacology and experimental therapeutics,
2002; 303(2):
527-33.
Murphy, D. L., Li, Q., Engel, S., Wichems, C., Andrews, A., Lesch, K. P., and Uhl, G.
Genetic perspectives on the serotonin transporter
Brain Research Bulletin,
2001; 56(5):
p. 487-494.
Sora, I., Hall, F. S., Andrews, A. M., Itokawa, M., Li, X. F., Wei, H. B., Wichems, C., Lesch, K. P., Murphy, D. L., and Uhl, G. R.
Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference
Proceedings of the National Academy of Sciences of the United States of America,
2001; 98(9):
p. 5300-3055.
Andrews, A. M.
The use of 2'-NH2-MPTP as a tool to probe central serotonin and norepinephrine neurotransmitter systems,
Neurotransmissions,
2000; 16:
p.18-21.
Bengel, D., Murphy, D. L., Andrews, A. M., Wichems, C. H., Feltner, D., Heils, A., Mossner, R., Westphal, H., and Lesch, K. P.
Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice
Molecular Pharmacology,
1998; 53(4):
p. 649-655.
Murphy, D. L., Andrews, A. M., Wichems, C. H., Li, Q., Tohda, M., and Greenberg, B.
Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs
Journal of Clinical Psychiatry,
1998; 59(Suppl 15):
p.4-12.
Tsao, L. I., Ladenheim, B., Andrews, A. M., Chiueh, C. C., Cadet, J. L., and Su, T. P.
Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species
Journal of Pharmacology and Experimental Therapeutics,
1998; 287(1):
322-331.
Bengel, D., Jöhren, O., Andrews, A. M., Heils, A., Mössner, R., Sanvitto, G. L., Saavedra, J. M., Lesch, K.-P., and Murphy, D. L.
Cellular localization and expression of the serotonin transporter in mouse brain
Brain Research,
1997; 778(2):
p. 338-345.
Bengel, D., Heils, A., Petri, S., Seemann, M., Glatz, K., Andrews, A., Murphy, D. L., and Lesch, K. P.
Gene structure and 5'-flanking regulatory region of the murine serotonin transporter
Brain Research: Molecular Brain Research,
1997; 44(2):
286-92.
Tella, S. R., Ladenheim, B., Andrews, A. M., Goldberg, S. R., and Cadet, J. L.
Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system
Journal Neuroscience,
1996; 16(23):
p. 7416-7427.
Andrews, A. M., Ladenheim, B., Epstein, C. J., Cadet, J. L., and Murphy, D. L.
Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals
Molecular Pharmacology,
1996; 50(6):
p. 1511-1519.
Alivisatos A Paul, Andrews Anne M, Boyden Edward S, Chun Miyoung, Church George M, Deisseroth Karl, Donoghue John P, Fraser Scott E, Lippincott-Schwartz Jennifer, Looger Loren L, Masmanidis Sotiris, McEuen Paul L, Nurmikko Arto V, Park Hongkun, Peterka Darcy S, Reid Clay, Roukes Michael L, Scherer Axel, Schnitzer Mark, Sejnowski Terrence J, Shepard Kenneth L, Tsao Doris, Turrigiano Gina, Weiss Paul S, Xu Chris, Yuste Rafael, Zhuang Xiaowei
Nanotools for neuroscience and brain activity mapping
ACS nano,
2013; 7(3):
1850-66.
Moya Pablo R, Wendland Jens R, Rubenstein Liza M, Timpano Kiara R, Heiman Gary A, Tischfield Jay A, King Robert A, Andrews Anne M, Ramamoorthy Samanda, McMahon Francis J, Murphy Dennis L
Common and rare alleles of the serotonin transporter gene, SLC6A4,
associated with Tourette's disorder
Movement disorders : official journal of the Movement Disorder Society,
2013; 28(9):
1263-70.